On Friday last week, AstraZeneca confirmed that their combination trial for osimertinib, as it’s expected to be called or AZD9291, as it’s more commonly known (anti-EGFR mutant, T790M inhibitor) plus durvalumab (MEDI–4736, anti-PD-L1) in non-small cell lung cancer (NSCLC) is on clinical hold following an increase in ‘interstitial lung disease-like reports.’
As companies with checkpoint inhibitors and other immunotherapy agents expand beyond monotherapy into logical combinations, is the risk of increased ILD from combining an EGFR inhibitor with a checkpoint something other companies need to watch out for?
By the way, we strongly disagree with the reported conclusion of Goldman Sachs on this issue – and here’s why…
Today’s article explores this controversial issue in more depth.
Subscribers can log in or you can purchase access in the box below.
It’s time for the August mailbag where we answer questions about cancer research and R&D from subscribers.
After the recent queries about immuno-oncology, it’s time to focus a little on targeted therapies again. Neither chemotherapies nor targeted therapies are going to go away – they are still the bedrock of many treatment approaches in the clinic today. Sadly though, much of the new data for the latter trials were easily swamped by the sheer tsunami of immunotherapy data in Philadelphia (AACR) and Chicago (ASCO).
One important area that we have been discussing on both blogs for some time is the value of well designed basket trials. It’s time to revisit this concept in the light of new data relating to the BRAF V600 mutation outside of metastatic melanoma.
Subscribers can log in below or you can sign up to read our latest article and Op-Ed on cancer research and oncology R&D.